<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03090841</url>
  </required_header>
  <id_info>
    <org_study_id>14024</org_study_id>
    <nct_id>NCT03090841</nct_id>
  </id_info>
  <brief_title>Biomarkers of Cytomegalovirus Fetal Infection and Disease</brief_title>
  <acronym>BIO-CCMV</acronym>
  <official_title>Biomarkers of Fetal Infection and Disease Following Maternal HCMV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to determine 1) if the diagnosis of CMV fetal infection could
      be done directly in the maternal blood instead of requesting an amniocentesis and 2) if
      innovative technologies such as proteomic, transcriptomic, methylomic and lipidomic applied
      in fetal samples could allow the discovery of new biomarkers of fetal infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Human cytomegalovirus (HCMV) is the most common cause of congenital infection worldwide. The
      diagnosis of CMV fetal infection relies on the detection of viral DNA in amniotic fluid by
      polymerase chain reaction after amniocentesis. Non-invasive diagnosis of fetal infection
      directly in maternal blood is not available. Symptoms develop in about 10% of HCMV-infected
      fetuses. Despite important advance in medical imaging, establishing the prognosis of an
      infected fetus remains challenging. Thrombocytopenia, blood HCMV DNA, anti-HCMV
      immunoglobulin M and β2-microglobulin are recognized biomarkers of symptomatic fetal
      infections. However, the predictive value of these individual markers is not. Omics
      technologies could help to establish multimarker signatures of symptomatic infections.

      The objective of the study is to:

        -  validate fetal blood HCMV DNA, anti-HCMV immunoglobulin M , β2-microglobulin and
           platelet count as biomarkers of fetal disease;

        -  identify new biomarkers of severe fetal disease using transcriptomic, methylomic and
           lipidomic analyses of fetal blood and of amniotic fluid.

        -  validate a non-invasive CMV fetal infection diagnosis tool based on deep-sequencing of
           targeted CMV genes in maternal blood
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Values in fetal blood</measure>
    <time_frame>At 23 weeks gestation +/- 3 weeks</time_frame>
    <description>Fetal platelet in mm3/ml, β2 microglobulinein mg/L, proteins concentration in mg/L , Metabolites concentration in mmoles/l , Lipids concentration in mmoles/l , RNA messagers concentration in µg/ml profil</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Values in amniotic fluid</measure>
    <time_frame>At 23 weeks gestation +/- 3 weeks</time_frame>
    <description>CMV DNA quantification in UI/mL , protein concentration in mg/L, Metabolites concentration in mmoles/l , Lipids concentration in mmoles/l, RNAm concentration in µg/ml profil ,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non invasive diagnosis of fetal CMV infection in maternal blood in UI/mL.</measure>
    <time_frame>At 23 weeks gestation +/- 5 weeks</time_frame>
    <description>CMV fetal DNA measurement in maternal blood</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">265</enrollment>
  <condition>Cytomegalovirus Congenital</condition>
  <arm_group>
    <arm_group_label>CMV cases</arm_group_label>
    <description>bio-specimen collected for pregnant women with CMV infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control cases</arm_group_label>
    <description>bio-specimen collected for pregnant women carrying a fetus with aneuploidy-dysgonosomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bio-specimen collected</intervention_name>
    <arm_group_label>CMV cases</arm_group_label>
    <arm_group_label>Control cases</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Amniotic fluid (2ml)

        -  Fetal blood (2 ml)

        -  Maternal blood (5 ml)

        -  Cord blood (50 ml)

        -  Neonatal blood (2 ml)

        -  Neonatal urine (2 ml
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  320 pregnant women with CMV primary infection or carrying a fetus with compatible
             ultrasound features to obtained 65 infected fetuses and 15 fetuses diagnosed with
             severely symptomatic infection

          -  200 controls pregnant women carrying a fetus with aneuploidy-dysgonosomy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        CMV cases:

          -  Informed consent obtained from the mother;

          -  Pregnant women either with a history of primary CMV infection in pregnancy or carrying
             a fetus with ultrasound features compatible with CMV infection and willing to have
             amniocentesis for fetal diagnosis of CMV infection

        Control cases :

        - Pregnant women carrying a fetus with aneuploidy-dysgonosomy

        Exclusion Criteria:

        CMV cases:

          -  Fetuses older than the 26 weeks of gestation at the time of diagnosis of HCMV
             infection or impossibility to collect foetal samples by the end of the 26th week of
             gestation

          -  Mother unable to understand the protocol

          -  Absence of informed consent

          -  Any clinical rationale not to perform cordocentesis

          -  Mother &lt;18 years age

          -  Administration of immunoglobulins or anti-viral therapy to the mother before the
             collection of fetal samples or before the diagnosis of symptomatic fetal infection

          -  Administration of anti-HCMV drugs to the foetus before the collection of fetal samples
             or before the diagnosis of symptomatic fetal infection

          -  Administration of immunosuppressive drugs to the mother during pregnancy

          -  Maternal auto immune disorders

          -  Multiple pregnancies.

        Control cases :

          -  Mother unable to understand the protocol

          -  Absence of informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves VILLE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianne LERUEZ, MD, PhD</last_name>
    <phone>+33 (0) 1 44 49 49 49 62</phone>
    <email>marianne.leruez@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurence LECOMTE, PhD</last_name>
    <phone>+33 1 71 19 64 94</phone>
    <email>laurence.lecomte@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Necker Enfants-Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne LERUEZ, MD, PhD</last_name>
      <phone>+33 (0) 1 44 49 49 49 62</phone>
      <email>marianne.leruez@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Benoist G, Salomon LJ, Jacquemard F, Daffos F, Ville Y. The prognostic value of ultrasound abnormalities and biological parameters in blood of fetuses infected with cytomegalovirus. BJOG. 2008 Jun;115(7):823-9. doi: 10.1111/j.1471-0528.2008.01714.x.</citation>
    <PMID>18485159</PMID>
  </reference>
  <reference>
    <citation>Fabbri E, Revello MG, Furione M, Zavattoni M, Lilleri D, Tassis B, Quarenghi A, Rustico M, Nicolini U, Ferrazzi E, Gerna G. Prognostic markers of symptomatic congenital human cytomegalovirus infection in fetal blood. BJOG. 2011 Mar;118(4):448-56. doi: 10.1111/j.1471-0528.2010.02822.x. Epub 2010 Dec 24.</citation>
    <PMID>21199291</PMID>
  </reference>
  <reference>
    <citation>Desveaux C, Klein J, Leruez-Ville M, Ramirez-Torres A, Lacroix C, Breuil B, Froment C, Bascands JL, Schanstra JP, Ville Y. Identification of Symptomatic Fetuses Infected with Cytomegalovirus Using Amniotic Fluid Peptide Biomarkers. PLoS Pathog. 2016 Jan 25;12(1):e1005395. doi: 10.1371/journal.ppat.1005395. eCollection 2016 Jan.</citation>
    <PMID>26808779</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytomegalovirus Congenital</keyword>
  <keyword>Non-invasive diagnosis</keyword>
  <keyword>Omics</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

